Size: | Price | Quantity | |
---|---|---|---|
5 mg | $75.00 | ||
25 mg | $240.00 |
CC-90009 (1860875-51-9) is a modulator of the cullin ring ligase 4-cereblon E3 ubiquitin ligase complex that specifically targets GSPT1 (G1 to S phase transition 1; EC50 = 9 nM; also known as eRF3a) instead of Ikaros (IKZF1) and Aiolos (IKZF3).1 It rapidly induced apoptosis and reduced leukemia engraftment and leukemia stem cells across a wide spectrum of acute myeloid leukemia xenograft patient samples including refractory/relapsed cases.2 The anti-AML activity of CC-90009 was shown to be regulated by multiple signaling pathways including the ILF/ILF3 complex, mTOR, and the integrated stress response. CC-90009 was able to potentiate premature termination codon (PTC; 11% of all genetic lesions in patients with inherited diseases contain this type of mutation) readthrough by aminoglycosides via degradation of eukaryotic release factors 1 (eRF1) and 3 (eRF3a/b) in various heritable disease models.3 It was also able to enhance aminoglycoside PTC readthrough of the mutated retinoblastoma (RB1) gene in MDA-MB-436 breast carcinoma cells and SW1783 astrocytoma cells.4
References/Citations:
C22H18ClF2N3O4
>98% by HPLC
NMR: (Conforms)
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
CC-90009 (1860875-51-9) is a modulator of the cullin ring ligase 4-cereblon E3 ubiquitin ligase complex that specifically targets GSPT1 (G1 to S phase transition 1; EC50 = 9 nM; also known as eRF3a) instead of Ikaros (IKZF1) and Aiolos (IKZF3).1 It rapidly induced apoptosis and reduced leukemia engraftment and leukemia stem cells across a wide spectrum of acute myeloid leukemia xenograft patient samples including refractory/relapsed cases.2 The anti-AML activity of CC-90009 was shown to be regulated by multiple signaling pathways including the ILF/ILF3 complex, mTOR, and the integrated stress response. CC-90009 was able to potentiate premature termination codon (PTC; 11% of all genetic lesions in patients with inherited diseases contain this type of mutation) readthrough by aminoglycosides via degradation of eukaryotic release factors 1 (eRF1) and 3 (eRF3a/b) in various heritable disease models.3 It was also able to enhance aminoglycoside PTC readthrough of the mutated retinoblastoma (RB1) gene in MDA-MB-436 breast carcinoma cells and SW1783 astrocytoma cells.4
References/Citations:
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.